Reviva Pharmaceuticals’ (RVPH) “Buy” Rating Reaffirmed at D. Boral Capital

Reviva Pharmaceuticals (NASDAQ:RVPH)‘s stock had its “buy” rating reaffirmed by research analysts at D. Boral Capital in a report released on Tuesday,Benzinga reports. They currently have a $15.00 target price on the stock.

Several other equities research analysts also recently issued reports on RVPH. Roth Capital upgraded shares of Reviva Pharmaceuticals to a “strong-buy” rating in a research report on Friday, January 10th. EF Hutton Acquisition Co. I raised Reviva Pharmaceuticals to a “strong-buy” rating in a report on Monday, September 23rd. Maxim Group upgraded shares of Reviva Pharmaceuticals from a “hold” rating to a “buy” rating and set a $7.00 price target on the stock in a research note on Friday, January 10th. Finally, Roth Mkm started coverage on shares of Reviva Pharmaceuticals in a research note on Friday, January 10th. They issued a “buy” rating and a $7.00 price objective for the company. Five investment analysts have rated the stock with a buy rating and two have given a strong buy rating to the company’s stock. Based on data from MarketBeat.com, the company has a consensus rating of “Buy” and a consensus target price of $12.00.

Reviva Pharmaceuticals Price Performance

Shares of RVPH opened at $1.77 on Tuesday. The firm has a 50-day moving average of $1.66 and a 200-day moving average of $1.32. The company has a market cap of $59.19 million, a PE ratio of -1.59 and a beta of -0.12. Reviva Pharmaceuticals has a one year low of $0.60 and a one year high of $4.83.

Institutional Inflows and Outflows

A hedge fund recently raised its stake in Reviva Pharmaceuticals stock. Geode Capital Management LLC raised its holdings in Reviva Pharmaceuticals Holdings, Inc. (NASDAQ:RVPH) by 17.9% in the 3rd quarter, according to the company in its most recent filing with the SEC. The firm owned 278,496 shares of the company’s stock after acquiring an additional 42,376 shares during the quarter. Geode Capital Management LLC owned approximately 0.83% of Reviva Pharmaceuticals worth $401,000 as of its most recent SEC filing. 63.18% of the stock is owned by institutional investors and hedge funds.

About Reviva Pharmaceuticals

Reviva Pharmaceuticals Holdings, Inc, a biopharmaceutical company, discovers, develops, and commercializes next-generation therapeutics for diseases targeting unmet medical needs in the areas of central nervous system, respiratory, inflammatory, and cardiometabolic diseases. The company's lead product candidate comprises brilaroxazine (RP5063) for the treatment of various neuropsychiatric indications, including schizophrenia, bipolar disorder, major depressive disorder, attentiondeficit/hyperactivity disorder, behavioral and psychotic symptoms of dementia and Alzheimer's disease, and Parkinson's disease psychosis; in clinical development respiratory indications, such as pulmonary arterial hypertension and idiopathic pulmonary fibrosis; and in preclinical development for the treatment of psoriasis.